Cipla shares rally on anti-asthma inhaler launch in Germany

Subscribe to GoodReturns
For Quick Alerts
For Daily Alerts

    Shares in Cipla jumped sharply by 7 per cent after the pharma major launched an anti-asthma inhaler in Germany and Sweden. the stock was last trading at Rs 564 on the Bombay Stock Exchange.

    The inhaler is a generic version of GlaxoSmithKline Plc's Advair.

    Noted broking firm, Emkay Global upgraded the stock to "buy" from "accumulate" with a target of 671 rupees.

    Overall addressable opportunity of generic Advair is $800 million in Europe, Emkay said.


    Cipla shares were trading up 7.1 percent to 566.75 rupees as of 10:02 a.m.

    Read more about: cipla
    Story first published: Tuesday, September 2, 2014, 11:05 [IST]
    Company Search
    Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

    Find IFSC

    Get Latest News alerts from Goodreturns

    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more